Latest Updates
Read the latest news that impacts the oncology community.
Trump demands pharma CEOs implement 'most favored nation' pricing within 60 days
President Donald Trump stepped up his campaign to get large drugmakers to lower their prices, posting letters to more than a dozen major pharma companies.
Read MorePrescription for made in America? Tariffs and U.S. drug manufacturing
Tariffs on U.S. pharmaceutical imports have been recently proposed. This article examines the potential effects of tariffs on U.S. domestic drug manufacturing, focusing on the differential impact on branded and generic drugs.
Read MorePBM markets are at risk of harming patients
CHICAGO — The American Medical Association (AMA) today published a new annual analysis (PDF) measuring competition in pharmacy benefit manager (PBM) markets and vertical integration of insurers with PBMs.
Read MoreChallenges and Opportunities for the US Oncology Workforce
The oncology workforce, already strained, will face increasing challenges in trying to care for the growing number of US patients with cancer and survivors in years to come.
Read MoreHow Insurers Hijacked the Doctor-Patient Relationship
Two decades ago, farming needed a revolution. Agriculture was in a death spiral of soil exhaustion, soaring fertilizer costs, and falling profits despite burgeoning yields. Don Campbell, a rancher in Canada and a leading voice in the resulting regenerative agriculture movement, said, “If you want to make small changes, change the way you do things; if you want to make major changes, change the way you SEE things.” Medicine might take a lesson from Mr. Campbell.
Read MoreDrug Shortages Have Serious Impacts on Cancer Care at Community Practices
Researchers surveyed 93 National Cancer Institute Community Oncology Research Program (NCORP) practices to determine how many had experienced a cancer care delivery problem associated with a drug shortage in the past 3 months. The researchers collected data from October 7, 2020, to June 3, 2024.
Read MoreDrug prices likely to rise with tariffs on EU
The trade deal between the U.S. and the European Union could hit the pharmaceutical industry with billions in new costs and ultimately drive up prices and limit access.
Read MoreEU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
July 28 (Reuters) - The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday.
Read MoreArkansas Pharmacists Association responds to court's block of new PBM reform law
LITTLE ROCK (KATV) — A federal judge has blocked a new Arkansas law that would have prohibited pharmacy benefit managers, or PBMs—middlemen companies who set drug prices—from owning their own pharmacies.
Read MoreFederal judge blocks Arkansas law barring pharmacy benefit managers from owning pharmacies in state
LITTLE ROCK, Ark. (AP) — A federal judge temporarily blocked on Monday Arkansas’ first-in-the-nation law that would have prohibited pharmacy benefit managers from owning pharmacies in the state.
Read More